Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer

American Journal of Health-System Pharmacy

Volumn 65, Issue 18, 2008, Pages 1703-1710

  Paul, Betsy ^a   Trovato, James A ^b   Thompson, Jennifer ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Blood levels; Breast neoplasms; Dosage; Drug administration; Drug interactions; Food; Half life; Lapatinib; Mechanism of action; Neoplasm metastasis; Pharmacokinetics; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ACNE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; AUTOPHOSPHORYLATION; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIVER DYSFUNCTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING;

EID: 52949147180     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070646     Document Type: Review

References (24)

1. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-43. [Erratum, N Engl J Med. 2007; 356:1487.]
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005; 10(suppl 3):20-9.
3. Nicolini A, Giardino R, Carpi A et al. Metastatic breast cancer: an updating. Biomed Pharmacother. 2006; 60:548-56.
4. National Comprehensive Cancer Network. Breast cancer. NCCN clinical practice guidelines in oncology. Version 1. 2007. www.nccn.org (accessed 2007 Mar 1).
5. Herceptin (trastuzumab) package insert. South San Francisco, CA: Genentech, Inc.; 2006 Nov.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92.
7. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist. 2006; 11:34-41.
8. Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23:5305-13.
9. Tykerb (lapatinib) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2007.
10. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006; 11:1047-57.
11. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastasis in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008; 26:1993-9.
12. Lin NU, Dieras V, Paul D et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007; 25(18S): abstract 1012.
13. Lin N, Paul D, Dieras V et al. Lapatinib and capecitabine for the treatment of brain metastasis in patients with HER2(+) breast cancer - an updated analysis from EGF105084. Paper presented at the 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; 2007 Dec.
14. Chu SC, Schwartz G, de Bono T et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol. 2007; 25:3753-8.
15. Cristofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Paper presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; 2006 Dec.
16. Iwata H, Toi M, Fujuwara Y et al. Phase II clinical study of lapatinib in patients with advanced or metastatic breast cancer. Paper presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; 2006 Dec.
17. Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol. 2007; 25(18S): abstract 1035.
18. Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. J Clin Oncol. 2007; 25(18S): abstract 1011.
19. Storniolo AM, Koehler M, Preston A et al. Cardiac safety in patients with metastatic breast cancer treated with lapatinib and trastuzumab. J Clin Oncol. 2007; 25(18S): abstract 514.
20. Sweetman R, Lacouture MT, Koehler M et al. Skin events (SE) among 1,126 patients with lapatinib (L), an oral dual ErB1/2 tyrosine kinase inhibitor (TKI). J Clin Oncol. 2007; 25(18S): abstract 9102.
21. Frassoldati A, Guarneri V, Cagossi K et al. LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone receptor positive HER2 negative breast cancer. Preliminary report of activity and cardiac tolerability. Paper presented at 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; 2007 Dec.
22. Reddy N, Cohen R, Whitehead B et al. A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther. 2007; 81:S16-7.
23. Ratain MI, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007; 25:1-2. Editorial.
24. Red book. Montvale, NJ: Thomson Healthcare; 2008:774.